Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Changing epidemiology of immune-mediated inflammatory diseases in immigrants: A systematic review of population-based studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Nutritional recommendations for gout: An update from clinical epidemiology

    Research output: Contribution to journalReviewpeer-review

  1. Fecal microbiota transplantation in hepatic encephalopathy: a systematic review

    Research output: Contribution to journalReviewpeer-review

  2. Postprandial Increase in Mesenteric Blood Flow is Attenuated in Parkinson's Disease: A Dynamic PC-MRI Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study

    Research output: Contribution to journalLetterpeer-review

View graph of relations

Background: Limited data exist regarding the disease course of coronavirus disease 2019 (COVID-19) and its relationship with immunosuppressants among patients with immune-mediated inflammatory diseases (IMIDs). Therefore, this study aims to investigate the association between COVID-19, frequent rheumatological, dermatological, gastrointestinal, and neurological IMIDs and immunosuppressants. Methods: We conducted a Danish population-based cohort study including all residents living within Capital Region of Denmark and Region Zealand from January 28th, 2020 until September 15th, 2020 with the only eligibility criterion being a test for SARS-CoV-2 via reverse transcription–polymerase chain-reaction. Main outcomes included development of COVID-19, COVID-19-related hospitalization and mortality. Results: COVID-19 was less common among patients with IMIDs than the background population (n = 328/20,513 (1.60%) and n = 10,792/583,788(1.85%), p < 0.01, respectively). However, those with IMIDs had a significantly higher risk of COVID-19-related hospitalization (31.1% and 18.6%, p < 0.01, respectively) and mortality (9.8% and 4.3%, p < 0.01, respectively), which were associated with patients older than 65 years, and presence of comorbidities. Furthermore, systemic steroids were independently associated with a severe course of COVID-19 (Odds ratio (OR) = 3.56 (95%CI 1.83–7.10), p < 0.01), while biologic therapies were associated with a reduced risk hereof (OR = 0.47 (95%CI 0.22–0.95), p = 0.04). Patients suspending immunosuppressants due to COVID-19 had an increased risk of subsequent hospitalization (OR = 3.59 (95%CI 1.31–10.78), p = 0.02). Conclusion: This study found a lower occurrence, but a more severe disease course, of COVID-19 among patients with IMIDs, which was associated with the use of systemic steroids for IMIDs and suspension of other immunosuppressants. This study emphasizes the importance of weighing risks before suspending immunosuppressants during COVID-19.

Original languageEnglish
Article number102613
JournalJournal of Autoimmunity
Volume118
Pages (from-to)1-8
Number of pages8
ISSN0896-8411
DOIs
Publication statusPublished - Mar 2021

    Research areas

  • Autoimmune diseases, COVID-19, Epidemiology, Immune-mediated inflammatory diseases, Immunosuppressive agents, Population-based, Age Factors, COVID-19 Nucleic Acid Testing, Humans, Middle Aged, Risk Factors, Immunosuppressive Agents/administration & dosage, Male, COVID-19/diagnosis, Inflammation/diagnosis, Denmark/epidemiology, Immunosuppression, SARS-CoV-2, Adult, Female, Aged

ID: 62310174